Mode
Text Size
Log in / Sign up
N/A N=142 Randomized Single-blind Treatment

Five, Plus Nuts and Beans for Kidneys

Chronic Kidney Disease · Hypertension

Enrolled (actual)
142
Serious AEs
9.9%
Results posted
Jun 2023
Primary outcome: Primary: Change in Urinary Albumin Excretion From Baseline to 4 Months — -28.6; -5.6 mg/g — p=0.17

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Coaching DASH group (C-DASH) (Behavioral); Self-Shopping DASH group (S-DASH) (Behavioral)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Nov 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Urinary Albumin Excretion From Baseline to 4 Months
-28.6; -5.6 0.17
SECONDARY
Change in Systolic Blood Pressure From Baseline to 4 Months
-1.4; 0.9 0.36
SECONDARY
Change in Systolic Blood Pressure From Baseline to 12 Months
1.5; -1.6 0.33
SECONDARY
Change in Urinary Albumin Excretion From Baseline to 12 Months
-11.5; -1.4 0.61

Summary

This Five, Plus Nuts and Beans for Kidneys Study is a single center, randomized controlled trial with 2 parallel arms testing the hypothesis that delivery of nutritional advice to adopt a Dietary Approaches to Stop Hypertension (DASH)-like diet and $30/week worth of fruits, vegetables, nuts and beans tailored to personal choices and availability in neighborhood stores, will reduce kidney damage in African Americans with hypertension and chronic kidney disease.

Eligibility Criteria

Inclusion Criteria

  • Self-identified African American race
  • Age 21 years or older
  • Clinical diagnosis of hypertension and have a urine Albumin-Creatinine Ratio (ACR) of ≥30 mg/g with or without estimated Glomerular Filtration Rate (GFR) 30-59 ml/min/1.73m2.
  • Must be under regular care with their Johns Hopkins Community Physicians (JHCP) or Johns Hopkins Outpatient Center (JHOC) physician (seen within the past 12 months).
  • Must have a systolic blood pressure of 9%).
  • Patients with a serum potassium >4.6 milliequivalent (mEq) /L45
  • Urine ACR ≥ 1,000 mg/g
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03299816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search